Validation of a quantitative 12-multigene expression assay (Oncotype DX® colon cancer assay) in Korean patients with stage II colon cancer: Implication of ethnic differences contributing to differences in gene expression

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 3817-3825

  Jeong, Duck Hyoun ^a   Kim, Woo Ram ^a   Min, Byung Soh ^a   Kim, Young Wan ^b   Song, Mi Kyung ^a   Kim, Nam Kyu ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University Wonju College of Medicine   (South Korea)

Author keywords

Adjuvant chemotherapy; Colonic neoplasms; Ethnic groups; Gene expression

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; COLON CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNIC DIFFERENCE; FEMALE; GENE EXPRESSION ASSAY; HUMAN; HUMAN TISSUE; IMMUNOLOGY TEST KIT; INSTRUMENT VALIDATION; INTERMEDIATE RISK POPULATION; KOREAN (PEOPLE); LOW RISK POPULATION; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATIENT IDENTIFICATION; PERINEURAL INVASION; PILOT STUDY; QUANTITATIVE ANALYSIS; RECURRENCE RISK; RISK ASSESSMENT; TUMOR DIFFERENTIATION;

EID: 84950288732     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S95543     Document Type: Article

References (26)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
2. Park HC, Shin A, Kim BW, et al. Data on the characteristics and the survival of Korean patients with colorectal cancer from the Korea central cancer registry. Ann Coloproctol. 2013;29(4):144-149.
3. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020-2029.
4. Moertel CG, Fleming TR, Macdonald JS, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol. 1995;13(12):2936-2943.
5. Schippinger W, Samonigg H, Schaberl-Moser R, et al. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer. 2007;97(8):1021-1027.
6. Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol. 2004;22(16):3395-3407.
7. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22(10):1797-1806.
8. National Comprehensive Cancer Network. National comprehensive cancer network guidelines, Colon cancer (Version 2.2015). Available from: http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed May 1, 2015.
9. O'Connell MJ, Lavery I, Yothers G, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. 2010;28(25):3937-3944.
10. Agesen TH, Sveen A, Merok MA, et al. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut. 2012;61(11):1560-1567.
11. Maak M, Simon I, Nitsche U, et al. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann Surg. 2013;257(6):1053-1058.
12. Gray RG, Quirke P, Handley K, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. 2011;29(35):4611-4619.
13. Venook AP, Niedzwiecki D, Lopatin M, et al. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013;31(14):1775-1781.
14. Yothers G, O'Connell MJ, Lee M, et al. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. J Clin Oncol. 2013; 31(36):4512-4519.
15. Ollberding NJ, Nomura AM, Wilkens LR, Henderson BE, Kolonel LN. Racial/ethnic differences in colorectal cancer risk: the multiethnic cohort study. Int J Cancer. 2011;129(8):1899-1906.
16. Kim NK, Park JK, Shin E, Kim YW. The combination of nuclear factor kappa B, cyclo-oxygenase-2 and vascular endothelial growth factor expression predicts poor prognosis in stage II and III colorectal cancer. Anticancer Res. 2014;34(11):6451-6457.
17. Micke P, Ohshima M, Tahmasebpoor S, et al. Biobanking of fresh frozen tissue: RNA is stable in nonfixed surgical specimens. Lab Invest. 2006;86(2):202-211.
18. Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124(7):979-994.
19. Hong SP, Min BS, Kim TI, et al. The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer. Eur J Cancer. 2012;48(8):1235-1243.
20. Clark-Langone KM, Sangli C, Krishnakumar J, Watson D. Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay. BMC Cancer. 2010;10:691.
21. Kim H, Nam SW, Rhee H, et al. Different gene expression profiles between microsatellite instability-high and microsatellite stable colorectal carcinomas. Oncogene. 2004;23(37):6218-6225.
22. Pino MS, Chung DC. Microsatellite instability in the management of colorectal cancer. Expert Rev Gastroenterol Hepatol. 2011;5(3):385-399.
23. Kim GP, Colangelo LH, Wieand HS, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol. 2007;25(7):767-772.
24. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247-257.
25. Reimers MS, Kuppen PJ, Lee M, et al. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients. J Natl Cancer Inst. 2014;106(11):1-8.
26. Renouf DJ, Woods R, Speers C, et al. Improvements in 5-year outcomes of stage II/III rectal cancer relative to colon cancer. Am J Clin Oncol. 2013;36(6):558-564.